Clin Psychopharmacol Neurosci.  2023 Feb;21(1):1-1. 10.9758/cpn.2023.21.1.1.

Continuous Small Efforts Lead to Desirable Outcomes

• Pae CU

• KMID: 2539644
• DOI: http://doi.org/10.9758/cpn.2023.21.1.1

Abstract

The current impact factor of Clinical Psychopharmacology and Neuroscience (CPN) is 3.731 which has substantially increased over the 7 years since the first scoring of 1.500 in 2015. CPN definitely needs to go forward based on the past wonderful developments. The annual submission rate has been increasing every year and the rejection rate has reached 60%, including editorial rejection, since 2020. Submissions from international researchers were also increased and have maintained until today; 44 of the 71 papers in 2018, 39 of 73 in 2019, 44 of 71 in 2020, 50 of 84 in 2021, and 44 of 80 in 2022 were from international contributions, which make up 60% of all published articles over the 5 years. With huge help of colleagues all over the world, CPN has been clearly expanding its role as a communication platform of preclinical and clinical psychopharmacology, and neuroscience as one of leading journals in Asia region. However, CPN also encounters a new turning point, and if we overcome it well, we believe that we will have a new opportunity to huge leap forward. CPN plans to make some changes in journal format creating new sections to include more intriguing and advancing reports as well as reinforcement of editorial board. CPN will always face innovation and reclamation to be a better scientific hub for researchers from all over the world. CPN will continuously strive to publish excellent and challenging research papers and we always look forward to receiving your valuable contributions.